DK169304B1 - Anvendelse af ponalrestat til fremstilling af et urinsyresænkende lægemiddel - Google Patents
Anvendelse af ponalrestat til fremstilling af et urinsyresænkende lægemiddel Download PDFInfo
- Publication number
- DK169304B1 DK169304B1 DK099488A DK99488A DK169304B1 DK 169304 B1 DK169304 B1 DK 169304B1 DK 099488 A DK099488 A DK 099488A DK 99488 A DK99488 A DK 99488A DK 169304 B1 DK169304 B1 DK 169304B1
- Authority
- DK
- Denmark
- Prior art keywords
- uric acid
- ponal
- pharmaceutically acceptable
- residue
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Fats And Perfumes (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Enzymes And Modification Thereof (AREA)
- Saccharide Compounds (AREA)
- Dental Tools And Instruments Or Auxiliary Dental Instruments (AREA)
- Semiconductor Lasers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB878704569A GB8704569D0 (en) | 1987-02-26 | 1987-02-26 | Therapeutic agent |
| GB8704569 | 1987-02-26 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK99488D0 DK99488D0 (da) | 1988-02-25 |
| DK99488A DK99488A (da) | 1988-08-27 |
| DK169304B1 true DK169304B1 (da) | 1994-10-10 |
Family
ID=10613007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK099488A DK169304B1 (da) | 1987-02-26 | 1988-02-25 | Anvendelse af ponalrestat til fremstilling af et urinsyresænkende lægemiddel |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US4895843A (ko) |
| EP (1) | EP0296695B1 (ko) |
| JP (1) | JPH01216931A (ko) |
| KR (1) | KR880009653A (ko) |
| AT (1) | ATE81005T1 (ko) |
| DE (1) | DE3874978T2 (ko) |
| DK (1) | DK169304B1 (ko) |
| ES (1) | ES2052701T3 (ko) |
| GB (2) | GB8704569D0 (ko) |
| GR (1) | GR3006256T3 (ko) |
| HU (1) | HU197845B (ko) |
| IE (1) | IE61934B1 (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5064830A (en) * | 1990-08-02 | 1991-11-12 | Pfizer Inc. | Lowering of blood uric acid levels |
| CA2685202C (en) | 2007-03-23 | 2017-11-28 | The Board Of Regents Of The University Of Texas System | Methods for treating allergic asthma |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE47592B1 (en) * | 1977-12-29 | 1984-05-02 | Ici Ltd | Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture |
-
1987
- 1987-02-26 GB GB878704569A patent/GB8704569D0/en active Pending
-
1988
- 1988-02-09 US US07/154,019 patent/US4895843A/en not_active Expired - Fee Related
- 1988-02-18 ES ES88301379T patent/ES2052701T3/es not_active Expired - Lifetime
- 1988-02-18 GB GB8803763A patent/GB2201343B/en not_active Expired - Lifetime
- 1988-02-18 AT AT88301379T patent/ATE81005T1/de not_active IP Right Cessation
- 1988-02-18 DE DE8888301379T patent/DE3874978T2/de not_active Expired - Fee Related
- 1988-02-18 EP EP88301379A patent/EP0296695B1/en not_active Expired - Lifetime
- 1988-02-24 HU HU88872A patent/HU197845B/hu not_active IP Right Cessation
- 1988-02-25 IE IE51588A patent/IE61934B1/en not_active IP Right Cessation
- 1988-02-25 DK DK099488A patent/DK169304B1/da not_active IP Right Cessation
- 1988-02-26 KR KR1019880002083A patent/KR880009653A/ko not_active Application Discontinuation
- 1988-02-26 JP JP63044019A patent/JPH01216931A/ja active Pending
-
1992
- 1992-11-16 GR GR920402597T patent/GR3006256T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB8704569D0 (en) | 1987-04-01 |
| DK99488D0 (da) | 1988-02-25 |
| GB2201343A (en) | 1988-09-01 |
| US4895843A (en) | 1990-01-23 |
| HUT46213A (en) | 1988-10-28 |
| GB8803763D0 (en) | 1988-03-16 |
| HU197845B (en) | 1989-06-28 |
| KR880009653A (ko) | 1988-10-04 |
| EP0296695A2 (en) | 1988-12-28 |
| EP0296695A3 (en) | 1990-07-18 |
| IE880515L (en) | 1988-08-26 |
| JPH01216931A (ja) | 1989-08-30 |
| DK99488A (da) | 1988-08-27 |
| DE3874978T2 (de) | 1993-02-18 |
| ES2052701T3 (es) | 1994-07-16 |
| ATE81005T1 (de) | 1992-10-15 |
| DE3874978D1 (de) | 1992-11-05 |
| GR3006256T3 (ko) | 1993-06-21 |
| EP0296695B1 (en) | 1992-09-30 |
| GB2201343B (en) | 1990-11-14 |
| IE61934B1 (en) | 1994-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2063598C (en) | Slimming pharmaceutical composition | |
| CA2450777C (en) | Use of c-src inhibitors alone or in combination with sti571 for the treatment of leukaemia | |
| CN103249417A (zh) | 用于治疗高尿酸血症及相关疾病的方法 | |
| Williams et al. | Nephrolithiasis | |
| JP2014065718A (ja) | 糖尿病性神経障害の治療用医薬品を製造するための３−ヒドロキシ−３−メチルグルタリル補酵素ａレダクターゼ阻害剤の使用 | |
| CN103298466B (zh) | 茶碱和非布索坦的联合治疗方法 | |
| US20140256748A1 (en) | 3,4-di-substituted pyridine compound, methods of using and compositions comprising the same | |
| EP1772149A1 (en) | Drug for prevention or treatment of diabetes | |
| WO2011163319A2 (en) | Activation of amp-protein activated kinase by oxaloacetate compounds | |
| Abraham et al. | Medical evaluation and management of calcium nephrolithiasis | |
| JP2618449B2 (ja) | アルコール中毒治療用薬剤 | |
| Alzahrani et al. | Evaluative role of family physician in diagnosis and management of gout in primary health care centers: A simple literature review | |
| WO2004017916A2 (en) | Cardiovascular therapy composition including transfer factor and therapeutic methods including use of the composition | |
| DK169304B1 (da) | Anvendelse af ponalrestat til fremstilling af et urinsyresænkende lægemiddel | |
| CA3134786A1 (en) | Methods for treating subjects with chronic kidney disease | |
| CN109908124A (zh) | 利用卤芬酯或卤芬酸以及第二尿酸降低剂治疗痛风患者中高尿酸血症的方法 | |
| EP0443028A1 (en) | Non-injection carcinostatic agent for suppressing occurrence of inflammation due to 5-fluorouracil and method for curing cancer | |
| US4255438A (en) | Method for reduction of cardiac mortality rate using pyrazolidine-3,5-diones | |
| Hess | 'Bad dietary habits' and recurrent calcium oxalate nephrolithiasis | |
| Tiselius et al. | Stone disease: diagnosis and medical management | |
| Scott et al. | The effect of allopurinol on urinary oxalate excretion in stone formers | |
| EA018442B1 (ru) | Применение l-карнитина для лечения гипертензии, для снижения систолического или пульсового давления крови у субъектов с предиабетом | |
| EP0075845B1 (en) | Uric acid-lowering composition, method and use | |
| MX2014012376A (es) | Metodo para tratar hiperucemia en pacientes con gota usando halofenato o acido halofenico y un agente anti - inflamatorio. | |
| Gluszek et al. | The significance of homocysteine in patients with hypertension |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B1 | Patent granted (law 1993) | ||
| PBP | Patent lapsed |